Table 2.
Gynecological cancer patients’ characteristics
| Parameter | 16 Mar–30 Apr 30 and 3 Nov–31 Dec 2019 | 16 Mar–30 Apr 30 and 3 Nov–31 Dec 2020 | Difference (%) | p value | 1 May–2 Nov 2019 | 1 May–2 Nov 2020 | Difference (%) | p value |
|---|---|---|---|---|---|---|---|---|
| Gynecological cancer patients diagnosed | ||||||||
| Number of patients | 29 | 16 | − 45% | 102 | 57 | − 44% | ||
| Age, median (range) | 60 (34–83) | 66 (28–93) | + 10% | p = 0.164* | 61 (25–96) | 62 (30–95) | + 1% | p = 0.568* |
| Reported tumor-associated symptoms at diagnosis | ||||||||
| No | 5 (17%) | 1 (6%) | − 11% | p = 0.426† | 23 (22%) | 19 (33%) | + 11% | p = 0.170† |
| Yes | 16 (55%) | 12 (75%) | + 20% | 60 (59%) | 34 (60%) | + 1% | ||
| Unknown | 8 (28%) | 3 (19%) | 19 (19%) | 4 (7%) | ||||
| Referral of patients | ||||||||
| Patients themselves without symptoms | 1 (3%) | 0 (0%) | − 3% | p = 0.118† | 0 (0%) | 0 (0%) | 0% | p < 0.001† |
| Patients themselves with symptoms | 0 (0%) | 0 (0%) | 0% | 3 (3%) | 16 (28%) | + 25% | ||
| Specialist | 20 (69%) | 13 (81%) | + 12% | 79 (78%) | 40 (70%) | − 8% | ||
| General practitioner | 2 (8%) | 3 (19%) | + 11% | 6 (6%) | 1 (2%) | − 4% | ||
| Emergency | 3 (10%) | 0 (0%) | − 10% | 2 (2%) | 0 (0%) | − 2% | ||
| Unknown | 3 (10%) | 0 (0%) | 12 (11%) | 0 (0%) | ||||
| Comorbidities | ||||||||
| None | 6 (20%) | 3 (19%) | − 1% | p = 0.751† | 28 (28%) | 26 (46%) | -18% | p = 0.010† |
| Yes | 16 (55%) | 11 (69%) | − 14% | 53 (52%) | 29 (51%) | -1% | ||
| Unknown | 7 (25%) | 2 (12%) | 21 (20%) | 2 (3%) | ||||
| Frontline therapy | ||||||||
| Operation | 22 (75%) | 10 (63%) | − 12% | p = 0.559† | 68 (66%) | 43 (74%) | + 8% | p = 0.677† |
| Neoadjuvant chemotherapy | 3 (11%) | 3 (19%) | + 8% | 17(17%) | 8 (14%) | − 3% | ||
| Neoadjuvant endocrine therapy | 0 (0%) | 0 (0%) | 0% | 0 (0%) | 0 (0%) | 0% | ||
| Radiation | 0 (0%) | 0 (0%) | 0% | 2 (2%) | 1 (2%) | 0% | ||
| Combined chemoradiation | 3 (11%) | 1 (6%) | -5% | 11 (11%) | 2 (4%) | − 7% | ||
| COVID associated treatment delay | 0 (0%) | 0 (0%) | 0% | 0 (0%) | 0 (0%) | 0% | ||
| Palliative therapy | 0 (0%) | 1 (6%) | + 6% | 3 (3%) | 2 (4%) | + 1% | ||
| Unknown | 1 (3%) | 1 (6%) | 1 (1%) | 1 (2%) | ||||
| Diagnosis | ||||||||
| Ovarian cancer | 13 (45%) | 9 (56%) | + 11% | p = 0.542† | 40 (39%) | 23 (40%) | + 1% | p = 0.558† |
| Endometrial cancer | 7 (24%) | 6 (38%) | + 14% | 29 (28%) | 19 (33%) | + 5% | ||
| Cervical cancer | 5 (18%) | 1 (6%) | − 12% | 19 (19%) | 5 (9%) | − 10% | ||
| Vulva cancer | 2 (7%) | 0 (0%) | − 7% | 6 (6%) | 6 (10%) | + 4% | ||
| Sarcoma | 1 (3%) | 0 (0%) | − 3% | 4 (4%) | 2 (4%) | 0% | ||
| Others | 1 (3%) | 0 (0%) | − 3% | 4 (4%) | 2 (4%) | 0% | ||
| FIGO stage ovarian cancer | ||||||||
| I | 3 (23%) | 1 (11%) | − 12% | p = 0.145† | 12 (30%) | 6 (26%) | − 4% | p = 0.795† |
| II | 1 (7%) | 0 (0%) | − 7% | 1 (3%) | 1 (4%) | + 1% | ||
| III | 7 (55%) | 5 (56%) | + 1% | 19 (48%) | 10 (44%) | − 4% | ||
| IV | 2 (15%) | 0 (0%) | − 15% | 6 (15%) | 6 (26%) | + 11% | ||
| Unknown | 0 (0%) | 3 (33%) | 2 (4%) | 0 (0%) | ||||
| FIGO stage endometrial cancer | ||||||||
| I | 7 (100%) | 5 (83%) | − 17% | p = 0.261† | 23 (80%) | 16 (85%) | + 5% | p = 0.218† |
| II | 0 (0%) | 0 (0%) | 0% | 1 (3%) | 2 (10%) | + 7% | ||
| III | 0 (0%) | 0 (0%) | 0% | 0 (0%) | 1 (5%) | + 5% | ||
| IV | 0 (0%) | 0 (0%) | 0% | 3 (10%) | 0 (0%) | -10% | ||
| Unknown | 0 (0%) | 1 (17%) | 2 (7%) | 0 (0%) | ||||
16 March 2020–30 April 2020 and 3 November 2020–31 December 2020 refers to the lockdown periods 1 and 2, respectively. 1 May 2020–2 November 2020 refers to the time between the two lockdowns
*Mann–Whitney U test
†χ2 test